Recruitment is underway for a clinical trial testing a vaccine candidate produced with The University of Queensland's molecular clamp technology against life-threatening respiratory viruses.

Hope is on the horizon for needle-phobic patients as Griffith University researchers have created a new influenza vaccine ...

The world's first bivalent mRNA vaccine candidate against respiratory syncytial virus, or RSV, kicked off Phase I clinical ...

Current guidelines recommend that pregnant people receive a vaccine against respiratory syncytial virus (RSV) -- which typically causes mild, cold-like symptoms in most adults but can be deadly for ...

The holidays are fast approaching along with cooler weather and various respiratory illnesses. Here's when to get your ...

Current guidelines recommend that pregnant people receive a vaccine against respiratory syncytial virus (RSV)-;which typically causes mild, cold-like symptoms in most adults but can be deadly for ...

Regarding hospitalizations among immunocompetent older adults, vaccine effectiveness was 83% for the GSK vaccine and 73% for ...

Infants are among the most susceptible to respiratory ... syncytial virus, or RSV. While they can receive passive protection ...

TORONTO — Health Canada has approved Moderna's mRNA vaccine to protect against respiratory syncytial virus in adults age 60 ...

For adults aged 60 years or older, respiratory syncytial virus (RSV) vaccination is effective for preventing associat ...

The NHS is urging eligible patients to protect themselves this winter by getting vaccinated against respiratory syncytial ...